Clinical trials: in Norway
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants…
- Trial name
- FORTITUDE-101 (NCT05052801)
- Testing
- Bemarituzumab, mFOLFOX6
- Where
- 300 sites in United States, Argentina and 35 more
- Volunteers
- 547 people
- Sponsor
- Amgen
Unresectable Pleural Mesothelioma
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab +…
- Trial name
- eVOLVE-Meso (NCT06097728)
- Testing
- Volrustomig, Pemetrexed, Carboplatin
- Where
- 151 sites in United States, Australia and 19 more
- Volunteers
- 863 people
- Sponsor
- AstraZeneca
Alcoholic Liver Disease (ALD), Alcohol Use Disorder
Elastography-based Brief Alcohol Intervention in Hospitalized Individuals
Harmful alcohol use is a common cause of hospital admissions and the leading cause of liver cirrhosis. Timely detection of liver disease is crucial to prevent liver disease progression and reduce alcohol-related harms.
- Trial name
- PREDILECTION (NCT07637539)
- Testing
- Elastography-based brief alcohol intervention
- Where
- 8 sites in Norway
- Volunteers
- 500 people
- Sponsor
- Oslo University Hospital
Transthyretin Amyloid Cardiomyopathy
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
The primary objective of this study is to access the efficacy of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the total…
- Trial name
- DepleTTR-CM (NCT06183931)
- Testing
- ALXN2220
- Where
- 213 sites in United States, Argentina and 25 more
- Volunteers
- 1,182 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
SSM, Mastocytosis, Indolent
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
This is a multi-part, randomized, double-blind, placebo-controlled Phase 2 clinical study comparing the safety and efficacy of bezuclastinib (CGT9486) plus best supportive care (BSC) with placebo plus BSC in patients with…
- Conditions
- SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis
- Trial name
- NCT05186753
- Testing
- Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B)
- Where
- 57 sites in United States, Australia and 13 more
- Volunteers
- 237 people
- Sponsor
- Cogent Biosciences, Inc.
Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous…
- Trial name
- firmMIND (NCT05429268)
- Testing
- Tafasitamab, Lenalidomide
- Where
- 61 sites in Bulgaria, Croatia and 12 more
- Volunteers
- 82 people
- Sponsor
- Incyte Corporation
Growth Hormone Deficiency in Children
A Research Study in Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day (REAL4)
The study compares 2 medicines for children who do not have enough hormone to grow: somapacitan given once a week (a new medicine) and Norditropin® given once a day (the medicine doctors can already prescribe).
- Trial name
- REAL4 (NCT03811535)
- Testing
- Somapacitan, Norditropin®
- Where
- 139 sites in United States, Algeria and 24 more
- Volunteers
- 200 people
- Sponsor
- Novo Nordisk A/S
Depression Moderate, Anxiety, Social
Effects and Cost-effectiveness of e-Meistring - a Guided Internet-delivered Psychological Treatment
The goal of this observational multicentre study is to address the effectiveness and cost-effectiveness of providing a therapist guided internet based cognitive behavioural therapy (ICBT) for common mental disorders in a routine…
- Conditions
- Depression Moderate, Anxiety, Social, Panic Disorder
- Trial name
- NCT05868135
- Testing
- eMeistring
- Where
- 4 sites in Norway
- Volunteers
- 800 people
- Sponsor
- St. Olavs Hospital
Liver Metastases, Colorectal Cancer
EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden
Patients with multiple colorectal liver metastases that progress on 1st line chemotherapy have a very dismal prognosis, and their options are few.
- Trial name
- EXCALIBUR3 (NCT04840186)
- Testing
- Liver-resection or ablation, 2nd line chemotherapy
- Where
- Norway
- Volunteers
- 62 people
- Sponsor
- Oslo University Hospital
Colorectal Cancer, Liver Metastases
HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.
Patients with colorectal livermetasteses and heavy tumour burden and progression on 1st line chemotherapy have no other available treatment in Norway today other than 2nd line chemotherapy.
- Conditions
- Colorectal Cancer, Liver Metastases, Chemotherapy Effect
- Trial name
- EXCALIBUR1+2 (NCT04898504)
- Testing
- Floxuridine, Liver Transplantation
- Where
- Norway
- Volunteers
- 39 people
- Sponsor
- Oslo University Hospital
Agitation in Dementia, Including Alzheimer's Disease
Virtual Darkness Theraphy for Agitation in Dementia
Behavioral and psychological symptoms of dementia (BPSD) such as anxiety, depression, psychosis and agitation, are prevalent, often treatment resistant, resource demanding and significantly deteriorates cognition, independency…
- Trial name
- DARKDEM (NCT06451952)
- Testing
- Virtual darkness
- Where
- Norway
- Volunteers
- 72 people
- Sponsor
- University of Bergen
Prostate Cancer
Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer
Thousands of men take a PSA test to investigate whether they have prostate cancer every year. For the vast majority, the test is normal and further investigations are not necessary.
- Trial name
- PRORAND (NCT07422597)
- Testing
- European Study of screening for prostate cancer risk calculator
- Where
- 3 sites in Norway
- Volunteers
- 1,016 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Stress Disorders, Post-Traumatic, Mental Disorders
Group-based Stabilization and Skill Training for Patients With Lasting Posttraumatic Reactions in Mental Health Care
This study evaluates the addition of a group based stabilization and skill-training intervention to individual out-patient treatment for long lasting post-traumatic reactions.
- Conditions
- Stress Disorders, Post-Traumatic, Mental Disorders, Trauma and Stressor Related Disorders
- Trial name
- NCT03887559
- Testing
- Group-based stabilization and skill training in addition to individual treatment, Treatment as usual
- Where
- Norway
- Volunteers
- 160 people
- Sponsor
- St. Olavs Hospital
Heart Transplantation
Donor Derived Cell Free DNA (Dd-cfDNA) as a Biomarker for Allograft Rejection in Heart Transplant Recipients
Following heart transplantation (HTx), lifelong immunosuppressive treatment is required to prevent the immune system from attacking, damaging, and rejecting the donor hear (allograft).
- Trial name
- TRANSCEND (NCT07886489)
- Testing
- Donor-derived cell free DNA
- Where
- 3 sites in Denmark, Norway
- Volunteers
- 100 people
- Sponsor
- University of Aarhus
Crohn's Disease
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely…
- Trial name
- STARSCAPE-1 (NCT07184931)
- Testing
- Duvakitug
- Where
- 461 sites in United States, Argentina and 34 more
- Volunteers
- 980 people
- Sponsor
- Sanofi
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
- Trial name
- BIOMEDE 2 (NCT05476939)
- Testing
- Everolimus, ONC201, Radiotherapy
- Where
- 56 sites in Belgium, Denmark and 6 more
- Volunteers
- 433 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Newly Diagnosed Multiple Myeloma (NDMM)
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
The purpose of this study is to measure the efficacy of AZD0120 compared with ASCT in terms of progression-free survival (PFS) according to the International Myeloma Working Group (IMWG) criteria 2016, and MRD negative complete…
- Trial name
- DURGA-6 (NCT07735637)
- Testing
- AZD0120, Cyclophosphamide, Fludarabine
- Where
- 114 sites in United States, Australia and 16 more
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Palliative Care, Patient Care
Dexmedetomidine for Refractory Pain in Palliative Cancer Patients
The goal of this study is to find out whether the medication dexmedetomidine can be a safe and effective additional treatment for cancer patients whose pain is not well controlled by standard pain medicines (such as opioids).
- Conditions
- Cancer, Palliative Care, Patient Care, Pain Management, Dexmedetomidine Analgesia
- Trial name
- DEX-PAL (NCT07885475)
- Where
- 4 sites in Norway
- Volunteers
- 30 people
- Sponsor
- St. Olavs Hospital
Olecranon Fracture
Treatment of Olecranon Fractures in the Elderly
Operative treatment, with tension band wiring or plate fixation, will be compared with non-operative treatment of displaced olecranon fractures (Mayo classification 2A and 2B) in patients 75 years or older.
- Trial name
- CROFT2 (NCT04670900)
- Testing
- Tension band wiring or plate fixation, Active non-operative treatment with optional plaster cast
- Where
- 12 sites in Norway, Sweden
- Volunteers
- 76 people
- Sponsor
- Oslo University Hospital